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Background: Natural killer (NK) cells can kill tumor cells in a non-MHC-restricted manner. However, cancer cells
frequently escape from the attack of NK cells by multiple ways. In this study, we investigated the effect of gefitinib
on the interaction between NK cells and lung cancer cells.
Methods: 51Cr release assay, CD107a assay, and IFN-γ secretion assay were performed to detect the sensitivity of
lung cancer cell lines A549 and H1975 to NK cells cytotoxicity in the presence of gefitinib. Human NK cells were
co-cultured with A549 and H1975 cell lines in the presence of gefitinib. NKG2D ligands, ULBP1, ULBP2, MICA, and
MHC-I on tumor cells, and NKG2D, NKp44 and NKp46 on NK cells were evaluated with flow cytometry. 51Cr release
assay was performed when NKG2D antibody were added into the co-culture system. Expressions of stat3 and LC3
I/II on tumor cells were determined with western blot after co-cultured with NK cells. After treated with gefitinib,
mannose-6-phosphate receptor (MPR) on H1975 cells was evaluated by flow cytometry. 51Cr release assay were
performed when MPR antagonist were used.
Results: Gefitinib increased cytotoxicity of NK cells to human lung cancer H1975 cells with EGFR L858R + T790M
mutations, while not in A549 cells with wild type EGFR. Gefitinib could block the immune escape by up-regulating
the expression of NKG2D ligands ULBP1, ULBP2 or MICA on tumor cells and NKG2D on NK cells in the co-culture
system. Gefitinib and NK cells up-regulated MHC-I expression in A549 while not in H1975 cells. NKG2D antibody
blocked the enhanced NK cytotoxicity by gefitinib. The combination of NK cells and gefitinib could significantly
down-regulate stat3 expression. Furthermore, NK cells-mediated tumor cell autophagy was observed in A549 cells
while not in H1975 cells. Notably, gefitinib increased autophagy and MPR expression in H1975 cells, which
improved the sensitivity to NK cell-based immunotherapy.
Conclusions: Gefitinib greatly enhanced NK cell cytotoxicity to lung cancer cells with EGFR L858R + T790M
resistance mutation. Combination of EGFR tyrokinase inhibitors and NK cells adoptive immunotherapy may
represent a potentially effective strategy for patients with non-small cell lung cancer.
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Lung cancer is a leading cancer death worldwide [1].
The use of selectively targeted agents has revolutionized
the treatment of lung cancer and shown promising clin-
ical activity. EGFR is frequently over-expressed in non-
small cell lung cancers (NSCLC) [2]. As the first small
inhibitor for EGFR, gefitinib induce dramatic clinical re-
sponses and improve progression-free survival, through
inhibition of EGFR-driven signals for tumor cells sur-
vival and proliferation [3]. However, many cancer pa-
tients invariably develop drug resistance [4-6]. The
secondary T790M mutation within the EGFR kinase
domain is a major mechanism of acquired resistance to
EGFR tyrosine kinase inhibitors (TKI) in NSCLC [7].
However, clinical response to gefitinib has been demon-
strated to be not correlated with EGFR levels, and
several other molecular mechanisms are also important
in predicting clinical response [8,9].
NK cells are key components of innate immunity and
participate in immunity against virus-infected and neo-
plastic cells [10]. NK cell-based immunotherapy may be
an efficient way to eliminate tumor cells, and many clin-
ical trials have been conducted and showed benefit [11].
NK cell can kill many cancer cells via direct killing,
induction of apoptosis or IFN-γ secretion [12,13]. Fur-
thermore, NK cells can inhibit tumor cell metastasis
[14]. Several activating receptors on NK cell surface have
been discovered, which are dispensable for NK cell acti-
vation [15,16]. The major receptors responsible for NK
cells activation are NKG2D and natural cytotoxicity re-
ceptors (NCRs; that is, NKp30, NKp44 and NKp46) [17].
NKG2D is the main activating receptor, and the binding
to its ligand can promote NK cells cytotoxic lysis of
target cells. Engagement of NKG2D activates NK cells
and then become a promising anti-cancer strategy [18,19].
MHC class I chain-related molecules, MICA and MICB,
and the UL16-binding proteins, ULBP-1, ULBP-2, and
ULBP-3 are the main ligands for human NKG2D, which
expressed on many cancer cells and infected cells [20,21].
Several clinical interventions have been demonstrated to
up-regulate NKG2D ligands expression on tumor cells and
enhance susceptibility to NK cells, including chemotherapy,
radiotherapy and HDAC-1 [22], Proteasome inhibitor [23].
However, several factors limited the efficiency of NK
cells adoptive therapy. Except for its poor ability to
home to tumor area, tumor microenvironment edited
NK cells and changed NK cell response [24-26]. Recent
reports showed that melanoma cells inhibited the ex-
pression of NK receptors and impaired NK cells cyto-
lytic functions [27]. NK cells per se can induce target
cell autophagy and enhance cancer cell survival [28].
Those results suggested that immunosuppressive bar-
riers developed by tumor cells could impair NK cells
based immunotherapy.Several immunomodulatory approaches have been
investigated to enhance anti-tumor therapy efficiency.
Imatinib potentiates antitumor T cell responses through
the inhibition of IDO [29]. Imatinib can act on host DCs
to promote NK cell activation [30]. In the present study,
we examine how gefitinib modulate the tumor cells and
NK cells after short-term interactions. We here show
that gefitinib enhance NK cells and tumor cells inter-
action by modulation of NKG2D ligands and NKG2D
and improve anti-tumor NK response. Gefitinib can
reduce stat3 expression in tumor cells. MPR expression-
induced by gefitinib can facilitate NK cell cytotoxicity in
human lung cancer cells with EGFR L858R + T790M
resistance mutation. Our results suggest that making use
of immunoregulatory property of gefitinib may be a po-
tential new therapeutical option for lung cancer with
EGFR L858 + T790M resistance mutation.Materials and methods
Cell culture
Human NSCLC cell lines A549 and H1975 were obtained
from American Type Culture Collection (ATCC; Manassas,
VA) and maintained in RPMI 1640 media (Hyclone)
supplemented with 10% FBS (GIBCO). NK cells were
obtained from peripheral blood of different health donors
by magnetic bead isolation using NK isolation kit (R&D
systems) according to the manufacturer’s instructions.
NK cell purity was >85%. All of the researches were
performed in accordance with the Sichuan University’s
Ethics Committees. NK cells were maintained in RPMI
1640 media supplemented with 200 U/ml IL-2 and
10 ng/ml IL-15 and 10% FBS.Flow cytometry
Primary NK cells were stained with CD56 (R&D sys-
tems) and CD3 antibodies (BD Pharmingen). Cells were
acquired on a FACSCalibur flow cytometer and data
were analyzed using Cell Quest software (BD Biosci-
ences). NK cells were co-cultured with the indicated tar-
get cells in a ratio of 1:1 in 24-well plates for 24 hours,
and 5 μg/ml gefitinib (Astra Zeneca) was added into
co-culture system for another 24 hours. Afterward, NK
cells were collected and examined for the expression of
NKG2D, NKp44, and NKp46. ULBP1, ULBP2, MICA
expression were evaluated on tumor cells. Intracellular
IFN-γ staining was performed after fixation in 2% para-
formaldehyde and permeabilization in 1% Trixton. IFN-
γ-PE antibody was purchased from BD Pharmingen.
Antibodies against NKG2D, NKp44, NKp46, ULBP1,
ULBP2, MICA were purchased from R&D systems. For
MPR expression, H1975 tumor cells were treated with
gefitinib for 48 hours, and then the MPR levels on cell
surface was evaluated by flowcytometry.
Figure 1 Gefitinib enhances cytotoxic activity of NK cells to
human lung cancer cells. (A-B), Primary human NK cells with high
purity were co-cultured with A549 (A) or H1975 tumor cells (B) in
the absence and presence of gefitinib for 4 hours. Cytotoxicity was
assessed using the 51Cr release assay. Data are expressed as means ±
SEM. * p < 0.05 , **p < 0.01.
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NK cells were co-cultured with the indicated target cells
in a ratio of 1:1 in the presence CD107a antibody (R&D
systems) for 4 h in the presence or absence of 5 μg/ml
gefitinib. Afterward, cells were washed and CD107a levels
on the NK cells were then analyzed by flow cytometry.
Western blot
Tumor cells were harvested and lysed in radio-
immunoprecipitation buffer for 30 min. Protein concen-
tration was determined by Bradford assay. Cell lysates
were resolved by SDS-PAGE, and transferred to PVDF
membrane (Millipore). Membrane was blocked in 5%
non-fat milk and then blots were probed with antibodies
for stat3 and LC3 (Cell Signaling Technology) respect-
ively. After incubated with horseradish peroxidase-
conjugated secondary antibodies, probes were visualized
by a chemiluminescent detection system. GAPDH as a
loading control. Antibody against GAPDH was obtained
from Cell Signaling Technology.
51Cr release assay
Target cells were labeled with 1 mCi of Na2
51CrO4 for
1 h at 37°C. Cells were then washed three times with
complete medium and incubated with effector cells at
different E:T ratios in the presence or absence of
5 μg/ml gefitinib. After incubation for 4 h at 37°C,
cell free supernatants were collected and counted on
scintillation counter. Percentage of cytolysis was cal-
culated by (sample release–spontaneous release)/(maximum
release–spontaneous release). To block the cytotoxicity of
NK cells, mannose-6-phosphate or 20 μg/mL NKG2D anti-
body (R&D system) were added into the 51Cr release assay
system.
Statistical analyses
ANOVA was used to identify significant group differ-
ences. p < 0.05 was considered statistically significant.
Results
Gefitinib enhanced cytotoxicity of NK cells in human lung
cancer cells with EGFR L858R + T790M mutation
To investigate whether gefitinib could increase the sus-
ceptibility of NSCLC cell lines to cytolytic activity of NK
cells, 51Cr releasing assay was performed. Two gefitinib
resistance NSCLC cell lines A549 (EGFR wt) and H1975
(EGFR L858R + T790M) were used. In the presence of
gefitinib, A549 showed some more enhanced susceptibility
to NK cells cytotxicity; however, there were no significant
difference (Figure 1A). As to H1975 with L858R + T790M,
gefitinib significantly improved NK cells cytotxicity
(Figure 1B). Those results suggested that gefitinib en-
hanced cytotoxicity of NK cells to human lung cancer
with EGFR L858R + T790M.Degranulation of NK cells triggered by gefitinib
CD107a degranulation was correlated with NK and T
cell killing [31]. The function of NK cells was evaluated
by measuring degranulation on the basis of CD107a
staining. In the presence of gefitinib, NK cells co-
incubated with H1975 degranulated more than did NK
cells from control group (Figure 2E-F). However, there was
no significant improvement in A549 cells (Figure 2C-D).
Our results suggested that gefitinib could enhance the abil-
ity of NK cell degradulation to lung cancer cells with EGFR
L858R + T790M.
Role of IFN-γ in the immunomodulation of gefitinib
IFN-γ has been demonstrated to be an important
effector cytokine produced by NK cells, which plays an
essential role in response to infection and tumors [32].
To determine whether gefitinib enhancement of NK cell
cytotoxicity was partially attributed to IFN-γ, we then
evaluated IFN-γ expression by NK cells. There were
no any improvements in IFN-γ secretion in A549
cells (Figure 3C-D). H1975 tumor cells inhibited IFN-
γ secretion from the NK cells (Figure 3E). However,
gefitinib significantly attenuated the inhibitory effect
of H1975 cells on NK cells IFN-γ secretion by after
24 hours stimulation (Figure 3F).
Figure 2 Gefitinib enhances NK cells degranulation. (A-B), NK cells was evaluated for CD107a levels in the absence (A) or presence (B) of
gefitinib. (C-D), NK cells were incubated for 4 h with A549 cell lines together with a CD107a antibody in the absence (C) or presence (D) of gefitinib.
(E-F), NK cells were incubated for 4 h with H1975 cell lines together with a CD107a antibody in the absence (E) or presence (F) of gefitinib. CD107a
levels were evaluated with flow cytometry. Two to three independent experiments were performed.
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cells and human lung cancer cells
Tumor cells impair NK cell-mediated killing by decreas-
ing expression of surface ligands for NK cell activating
receptors, which include NKG2D and NCRs [33,34]. To
investigate whether gefitinib could up-regulate surface
ligands for NK cell activating receptors, we co-cultured
two human lung cancer cell lines with NK cells and eval-
uated the expression of ULBP1, ULBP2 and MICA by
flowcytometry. ULBP1, ULBP2 and MICA were down-
regulated after co-culture of NK cells and H1975 cell
line (Figure 4B). In A549, ULBP2 and MICA expression
were down-regulated (Figure 4A). Those results sug-
gested that human lung cancer cells could decrease
expression of surface ligands for NKG2D. However, once
gefitinib was administered, ULBP1, ULBP2 and MICA
were all up-regulated in A549 cells (Figure 4A). In the
H1975 cell line, gefitinib could only up-regulate ULBP1
expression (Figure 4B). Our resultes suggested thatgefitinib could partially increase expression of surface
ligands for NKG2D and enhance immune recognition of
cancer cells by NK cells.
To investigate whether gefitinib influence the MHC-I
expression during the short interaction between NK cells
and tumor cells, we evaluated the MHC-I levels on
tumor cells. In A549 cell line, gefitinib and NK strikingly
up-regulated the MHC-I expression (Figure 5), while
the expression of MHC-I was slightly down-regulated
in H1975 cell line (Figure 5). Collectively, these re-
sults suggested that gefitinib and NK cells could up-
regulate the MHC-I in human lung cells with wild type
EGFR, while not significantly influence the MHC-I
expression on human lung cells with wild type EGFR
L858R + T790M.
On the other side, to investigate whether gefitinib
could affect NCRs and NKG2D expression on NK cells,
we detected NCRs and NKG2D expression by flow cy-
tometry. NCRs had no significant changes; however, we
Figure 3 Gefitinib increases IFN-γ production of NK cells. (A-B), NK cells was evaluated for the IFN-γ secretion in the absence (A) or presence
(B) of gefitinib. (C-D), NK cells were incubated with A549 cell lines in the absence (C) or presence (D) of gefitinib. (E-F), NK cells were incubated
with H1975 cell lines in the absence (E) or presence (F) of gefitinib. Intracellular IFN-γ levels were evaluated with flow cytometry. Two
independent experiments were performed.
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nificantly up-regulated, especially after co-cultured with
H1975 tumor cells (Figure 6A). To evaluate whether
NKG2D mediated the enhanced cytotoxicity of NK cells
by gefitinib, NKG2D antibody was added into the co-
culture system. 51Cr release assay showed that NKG2D
antibody significantly blocked the enhanced cytotoxicity
of NK cells by gefitinib (Figure 6B).
Role of stat3 in the immunomodulation of gefitinib
Activation of Stat3 has been demonstrated in a variety of
tumors. Stat3 can be phosphorylated by activated EGFR
and promote tumor survival in vivo in NSCLC [35].
Stat3 is a key factor in gefitinib-resistant EGFR T790M
cells [36]. Recent reports have demonstrated that Stat3
exerts an inhibitory effect on antitumor NK cell immun-
ity [37]. To determine if gefitinib reversal of tumor cells
mediated inhibition of NK cell activation was associated
with the inhibition of stat3, we quantified the expression
of stat3 in the tumor cells with western blot. As expected,gefitinib treatment alone for 24 hours substantially de-
creases stat3 expression (Figure 7A). Combination of
gefitinib with NK cells can further down-regulate stat3 in
H1975 cells (Figure 7A).
MPR expression-induced by gefitinib enhanced the NK
cytotoxity
Although gefitinib could restore NKG2D receptor-ligand
interactions between NK cells and human lung cancer
cells, and inhibit stat3 expression, further molecular
mechanisms should be investigated on the difference be-
tween A549 and H1975 to the sensitivity to gefitinib-
mediated NK cells response. Recent report suggested
that autophagy induced by conventional chemotherapy
could mediate tumor cell sensitivity to immunotherapy
[38]. To test whether the response difference was caused
by autophagy, autophagic marker LC3 was evaluated.
We found that gefitinib could increase autophagy in
H1975, as demonstrated by the enhanced conversion of
LC3-I to LC3-II (Figure 7A), While there was no
Figure 4 Gefitinib up-regulates NKG2Dligands on tumor cells. (A-B), ULBP1, ULBP2 and MICA expression was evaluated on A549 (A) and
H1975 (B) tumor cells after co-culture with NK cells in the presence or absence of gefitinib. Two independent experiments were performed.
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we also found that NK cells per se induced autophagy in
A549 cells, while not in H1975 cells (Figure 7A).
Autophagy can induce mannose-6-phosphate receptor
expression in murine tumor cells [38]. To test whether
gefitinib-induced autophagy can up-regulate MPR expres-
sion on human tumor cells, we treated H1975 cells for
48 hours with gefitinib and the analyzed the cell mem-
brane MPR expression by flow cytometry. We found thatMPR expression was obviously up-regulated after gefitinib
treatment (Figure 7B). Then, we further investigated
whether gefitinib-induced MPR expression could enhance
the cytotoxicity of NK cells. We used MPR antagonist
mannose-6-phosphate to block MPR and performed the
51Cr releasing assay. MPR blockade significantly impaired
the cytotoxic function of NK cells (Figure 7C). Together,
these results suggested that MPR expression-induced by
gefitinib could enhance the NK cytotoxity.
Figure 5 Gefitinib changes MHC-I expression on tumor cells. (A-B), MHC-I expression was evaluated on A549 (A) and H1975 (B) tumor cells
after co-culture with NK cells in the presence or absence of gefitinib. Two independent experiments were performed.
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Reasons for the failure of immune cell based therapy
have been advanced [39]. Tumor cells can employ a
variety of mechanisms to evade immune surveillance. In
our short-term co-culture system, A549 and H1975 lung
cancer cells down-regulated surface expression of
NKG2D ligands ULBP1, ULBP2 and MICA following
co-culture with NK cells. Those ligands facilitate NK
cells recognition of tumor cells and render tumor cells
susceptible to NK cell-mediated cytolysis [40]. Down
regulation of those ligands may help to evade NKG2D-
mediated immunosurveillance. NKG2D ligands may rep-
resent a potential target for evoking the innate immune
response against tumors. Approaches to activate NK
cells by up-regulating of NKG2D ligands on tumor cells
have been investigated. Our present study and those of
others showed that geftinib can partially up-regulate
NKG2D ligands ULBP1, ULBP2 or MICA on tumor cells
[34]. We also found gefitinib or NK cells could enhance
MHC-I expression, which impairs the recognization of
NK cells, in lung tumor cells with wild type EGFR, while
not in those with EGFR L858R + T790M. NKG2D is the
main activation receptor that potently stimulates cyto-
toxicity and production of IFN-γ by NK cells [41].
Lymphocyte activation integrates multiple signals. NK
cells express a plethora of cell surface markers belonging
to the TNFR family, such as CD27, CD137 (4-1BB),
CD134 (OX40) and glucocorticoid-induced TNFR (GITR),
which play important roles in immune synapses [42].
CD137-specific agonist antibodys increase trastuzumab-
mediated NK cell cytotoxicity and enhance trastuzumab
efficacy against human breast cancer [43]. The other
known activating NK cell receptors include NKG2D,
NCRs, 2B4, NTB-A and NKp80, CS1 [44] and the
leukocyte adhesion molecule DNAM-1 [45]. Here, wefocus our study on NKG2D and NCRs, which are recog-
nized as the main triggering receptors of NK cells
that are involved in target cell lysis. NCRs recognizes
yet uncharacterized ligands on tumor cells. We here
found the gefitinib up-regulated markedly NKG2D
levels on human NK cells in the co-culture of human
H1975 lung cancer cells, while NKp44 and NKp46
expression was less influenced. NKG2D plays an im-
portant role in immunosurveillance. Aberrant loss of
NKG2D in cancer is a important mechanism of immune
evasion. Reduced expression of NKG2D on NK and T cells
of cancer patients has been reported [40,46]. We then
examined NKG2D expression on NK cells and found that
geftinib up-regulated NKG2D expression on NK cells, and
we further found that the enhanced NK cytotoxicity by
gefitinib was mediated by NKG2D. The functional rele-
vance of restoration of NKG2D–NKG2DL interaction by
gefitinib was demonstrated by the enhanced cytotoxicity,
degranulation and IFN-γ production of NK cells in re-
sponse to lung cancer cells with EGFR L858R + T790M
resistance mutation.
Recently, immune system has been demonstrated to
contribute substantially to the antitumor effects of small
molecule inhibitors. Through the inhibition of IDO,
imatinib potentiates antitumor T cell responses in gastro-
intestinal stromal tumor [29]. Imatinib can also act on
host DCs to promote NK cell activation [30]. In our
present work, we find that, beyond its EGFR tyrokinase
inhibitory effect, gefitinib also has immunomodulatory
effect in gefitinib-resistance cell lines, which can enhance
immune recognization of tumor cells by NK cells and
attenuate the inhibitory effect of tumor cells on NK cells.
One of the major reasons for the weak effect of
cell based immunotherapy is thought to be immunosup-
pression. Tumor microenvironment, with abundant of
Figure 6 Gefitinib enhances NK cells cytotoxicity via NKG2D. (A) Gefitinib up-regulated NKG2D on NK cells. NKG2D, NKp44 and NKp46
expression was examined on NK cells following co-culture with A549 and H1975 tumor cells. Three independent experiments were performed.
(B) NKG2D antibody blocked the enhanced NK cells cytotoxicity by gefitinib. The concentration of NKG2D antibody was 20 μg/mL. * p < 0.05,
**p < 0.01.
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effector cells and result in insufficient antitumor effects
[24-26]. Stat3 plays an important role in the process
in tumor immunosuppression. Activation of IL-6R/
JAK1/STAT3 signaling can induce de novo resistance
in NSCLC with T790M resistance mutation [47]. Acti-
vation of stat3 has been demonstrated to lead to the
production of multiple immunosuppressive cytokines
[48]. Stat3 exerts an inhibitory effect on antitumor
NK cell immunity, and Stat3 knockdown decreases
MHC class I expression on lung tumor cells and re-
sults in the activation of NK cell-mediated cytotox-
icity [37]. We found that gefitinib could inhibit stat3
expression in lung cancer cells. Furthermore, combination
of gefitinib and NK cells can further reduce stat3 expres-
sion. We postulate that the attenuation of inhibitory effect
of tumor cells on NK cells may partially attributed to the
stat3 inhibition by gefitinib.In our present study, we also find that high purity NK
cells increase autophagy in A549 cancer cells with wide
type EGFR, while not in H1975 cells with EGFR L858R +
T790M. Lymphocyte provides lytic signals to tumor cells,
and they also promote autophagy in the remaining tumor
cells. These processes are primarily mediated by NK cells
[28]. Cell-mediated autophagy promotes cancer cell sur-
vival and induces resistance to subsequent therapies [28].
NK cell-induced autophagic change may promote cancer
cells survival. From the perspective of view, NK cells
therapy alone may not be an effective strategy. Though
gefitinib can also restore NKG2D ligands and NKG2D
interaction, and inhibit stat3 expression, we did not find
significant improvement on NK cells cytotoxicity to
A549 cells with wild type EGFR, while there was signifi-
cant enhancement to H1975 cells with EGFR L858R +
T790M resistance mutations. The elevated MHC-I
expression induced by gefitinib or NK cells may block
Figure 7 Stat3, autophagy and MPR expression are engaged in the immunoregulation of gefitinib. (A), after co-culture with NK cells in
the presence or absence of gefitinib, A549 and H1975 cells were evaluated for stat3 expression and LC3 levels with western blot. (B), MPR
expression was elevated on H1975 tumor cells treated with gefitinib. (C), MPR antagonist mannose-6-phosphate impaired the cytotoxic function
of human NK cells to H1975 tumor cells treated with gefitinib. Cytotoxicity was assessed with the 51Cr release assay. Data are expressed as means ±
SEM. * p< 0.05.
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suggests that autophagy caused by chemotherapy can
improve tumor cell sensitivity to immunotherapy, which
is mediated by up-regulating mannose-6-phosphate
receptor on the tumor cell surface [38]. We find that
gefitinib can enhance autophagy in the cell lines with
L858R + T790M and up-regulate the cell surface MPR
expression. MPR antagonist mannose-6-phosphate re-
duces the cytoxicity of NK cells. The enhanced NK cells
cytotoxicity by gefitinib may be attributed to elevated
MPR expression induced by gefitinib.
Conclusions
Our present study suggests that gefitinib has multiple
effects on the interaction between NK cells and tumorcells. Similar to imatinib, gefitinib has its own immuno-
modulatory property, which can enhance NK cell cyto-
toxicity. Gefitinib enhances NKG2D-NKG2D ligands
interaction between NK cells and human lung cancer
cells. Combination of gefitinib with NK cells down-
regulates stat3 expression. MPR expression induced by
gefitinib facilitates antitumor NK cell immunity. Thera-
peutic significance of our finding is that administration
of gefitinib may offer a novel adjuvant strategy to en-
hance NK cells based immunotherapy in NSCLC with
EGFR L858R + T790M resistance mutation.
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